The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for efficacy on October 27, 2025. This significant regulatory decision expands the approved therapeutic scope of the drug, reflecting new data supporting its use.
Background
Opdivo Qvantig is a specific formulation that combines nivolumab with hyaluronidase-nvhy, developed and marketed by Bristol-Myers Squibb. Supplemental applications, such as this one, are typically submitted to the FDA when a sponsor seeks to expand an existing drug's approved indications, add new patient populations, or update dosing and administration guidelines based on new clinical efficacy data.
What this means
This supplemental efficacy approval for Opdivo Qvantig signifies that the FDA has reviewed and accepted new clinical evidence demonstrating the drug's effectiveness for an expanded or modified therapeutic use. For clinicians, this means an expanded set of treatment options or patient populations where Opdivo Qvantig can be appropriately utilized, potentially offering new strategies for managing relevant conditions.
Source
The information regarding this regulatory action was sourced from the U.S. Food and Drug Administration (FDA) through its official database. Details are available for supplemental application BLA 761381 S-2, with the approval date noted as October 27, 2025, accessible via accessdata.fda.gov.